TP53 and acute myeloid leukemia: In addition, we provide an in‐depth characterization and prognostic evaluation of TP53MUT AML‐MRC, revealing that (A) the overall adverse prognosis in AML‐MRC is largely driven by TP53 mutation status and not AML‐MRC‐defining criteria, and (B) TP53 mutation confers an adverse prognostic impact in AML‐MRC irrespective of its allelic state or VAF.